To prevent enrichment of candidates against a single target, and thus reduce risk in the overall drug discovery portfolio for Chagas disease, it has therefore become necessary to evaluate and prioritise medicinal chemistry resource on new chemical series active against T. cruzi but with such activity not likely driven via T. cruzi CYP51 inhibition. The gene discussed is CYP51A1; the disease is Chagas disease.